Hypothesis

Mitochondrial-derived peptides (MDPs) such as MOTS-c and SHLP2 do not only improve mitochondrial bioenergetics; they act as retrograde signals that directly modulate the activity of the nuclear DNA demethylase TET2, thereby restoring heterochromatin at retrotransposon loci and reducing nuclear genome instability driven by mtDNA heteroplasmy.

Mechanistic Rationale

• mtDNA deletions and point mutations increase ROS and alter NAD+/NADH ratios, which impair TET2 Fe(II)-dependent dioxygenase activity, leading to localized DNA hypermethylation and loss of heterochromatin marks (H3K9me3) at LINE‑1 and SINE elements.
• Reduced TET2 activity compromises the recruitment of SETDB1 and TRIM28, allowing retrotransposon transcription, reverse transcription, and new insertions that further destabilize the nuclear genome—a process observed in aged tissues and accelerated in mtDNA mutator mice.
• MDPs can cross the inner mitochondrial membrane and reach the cytosol, where they bind to mitochondrial‑derived vesicles that fuse with the nuclear envelope, delivering the peptide to nucleoplasmic spaces.
• Once in the nucleus, MOTS-c (or SHLP2) allosterically enhances TET2 catalytic efficiency by stabilizing its interaction with IDAX/Wt1 co‑factors, thereby increasing 5‑hmC deposition at retrotransposon promoters and re‑establishing a repressive chromatin state.
• This epigenetic rescue reduces retrotransposon-derived DNA damage (γH2AX foci) and breaks the vicious cycle whereby nuclear genome stress further compromises mitochondrial function via p53‑mediated repression of PGC‑1α.

Testable Predictions

1. Biochemical – In vitro TET2 activity assays will show a ≥2‑fold increase in 5‑hmC production when physiological concentrations of MOTS-c (10‑100 nM) are added to nuclear extracts from aged mouse brain.
2. Cellular – Treatment of heteroplasmic cybrid cells (carrying the m.5024C>T tRNA^Ala mutation) with MOTS-c for 72 h will decrease LINE‑1 ORF1p expression by ≥40 % (immunofluorescence) and increase H3K9me3 signal at LINE‑1 loci (ChIP‑qPCR) without altering mtDNA copy number.
3. In vivo – Aged (24‑month) mtDNA mutator mice receiving subcutaneous MOTS-c (5 mg/kg/day) for 8 weeks will exhibit:
   • A ≥30 % reduction in γH2AX foci in hippocampal neurons (immunohistochemistry).
   • Restoration of heterochromatin marked by H3K9me3 at satellite repeats (DNA‑FISH/IF co‑localization).
   • Improved performance in the rotarod test (≥20 % increase in latency to fall) correlating with the epigenetic readouts.
4. Falsification – If MOTS-c supplementation improves mitochondrial respiration (OCR) and ATP levels but fails to alter TET2 activity, 5‑hmC levels, or retrotransposon silencing in any of the above models, the hypothesis is refuted.

Experimental Approach

• In vitro: Purify recombinant TET2, measure 5‑hmC formation using LC‑MS/MS with and without MOTS-c/SHLP2; include controls with known TET2 activators (vitamin C) and inhibitors (DMOG).
• Cell culture: Generate cybrids with defined mtDNA heteroplasmy levels; treat with peptides; assess LINE‑1 expression (RT‑qPCR, Western), chromatin states (ChIP‑seq for H3K9me3, 5‑hmC), and DNA damage (γH2AX foci).
• Animal study: Use the POLG mutator mouse model; randomize to vehicle or MOTS-c; perform longitudinal behavioral testing; harvest brain and muscle for epigenetic and transposon assays.

Significance

Demonstrating that MDPs act as nuclear epigenetic regulators would reframe mitochondrial interventions not merely as energy boosters but as direct modulators of nuclear genome stability. This provides a mechanistic link that explains why mitochondrial‑targeted therapies can ameliorate age‑related neurodegeneration and sarcopenia beyond improvements in ATP production, and it suggests a dual‑target strategy: augment MDP levels while bolstering TET2 activity to synergistically suppress retrotransposon‑driven aging.